@article{RN399,
   author = {Reyes, C. and Newby, D. and Raventós, B. and Verhamme, K. and Mosseveld, M. and Prieto-Alhambra, D. and Burn, E. and Duarte-Salles, T.},
   title = {Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study},
   journal = {Age Ageing},
   volume = {53},
   number = {5},
   note = {1468-2834 Reyes, Carlen Orcid: 0000-0001-8486-3265 Newby, Danielle Raventós, Berta Verhamme, Katia Mosseveld, Mees Prieto-Alhambra, Daniel Orcid: 0000-0002-3950-6346 Burn, Edward Duarte-Salles, Talita Real World Epidemiology/ Agency for Management of University and research/ Journal Article Multicenter Study Research Support, Non-U.S. Gov't England 2024/05/24 Age Ageing. 2024 May 1;53(5):afae106. doi: 10.1093/ageing/afae106.},
   abstract = {BACKGROUND: An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data. SETTING: Primary care data (country/database) from the UK/CPRD-GOLD (2007-20), Spain/SIDIAP (2010-20) and the Netherlands/IPCI (2008-20), standardised to a common data model. METHODS: Cohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)). RESULTS: We identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI.In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891-32,862)) to 2010 (17,793 (17,083-18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021-25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199-52,855)) to 2020 (14,571 (14,109-15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967-29,031)) to 2020 (4763 (4176-5409)). Subjects aged ≥65-79 years and men (in the UK and the Netherlands) initiated more frequently an ADD. CONCLUSIONS: Treatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.},
   keywords = {Humans
Male
Female
*Dementia/drug therapy/epidemiology
Aged
Aged, 80 and over
Middle Aged
Netherlands/epidemiology
Databases, Factual
Time Factors
Nootropic Agents/therapeutic use
Spain/epidemiology
United Kingdom/epidemiology
Practice Patterns, Physicians'/trends
Age Factors
Drug Utilization/trends/statistics & numerical data
cohort studies
dementia
drug utilization studies
older people},
   ISSN = {0002-0729 (Print) 0002-0729},
   DOI = {10.1093/ageing/afae106},
   year = {2024},
   type = {Journal Article}
}

{"_id":"6R24Dsgj6TjJ76MmL","bibbaseid":"reyes-newby-ravents-verhamme-mosseveld-prietoalhambra-burn-duartesalles-trendsofuseandcharacterisationofantidementiadrugsusersalargemultinationalnetworkpopulationbasedstudy-2024","author_short":["Reyes, C.","Newby, D.","Raventós, B.","Verhamme, K.","Mosseveld, M.","Prieto-Alhambra, D.","Burn, E.","Duarte-Salles, T."],"bibdata":{"bibtype":"article","type":"Journal Article","author":[{"propositions":[],"lastnames":["Reyes"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Newby"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Raventós"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Verhamme"],"firstnames":["K."],"suffixes":[]},{"propositions":[],"lastnames":["Mosseveld"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Prieto-Alhambra"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Burn"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Duarte-Salles"],"firstnames":["T."],"suffixes":[]}],"title":"Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study","journal":"Age Ageing","volume":"53","number":"5","note":"1468-2834 Reyes, Carlen Orcid: 0000-0001-8486-3265 Newby, Danielle Raventós, Berta Verhamme, Katia Mosseveld, Mees Prieto-Alhambra, Daniel Orcid: 0000-0002-3950-6346 Burn, Edward Duarte-Salles, Talita Real World Epidemiology/ Agency for Management of University and research/ Journal Article Multicenter Study Research Support, Non-U.S. Gov't England 2024/05/24 Age Ageing. 2024 May 1;53(5):afae106. doi: 10.1093/ageing/afae106.","abstract":"BACKGROUND: An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data. SETTING: Primary care data (country/database) from the UK/CPRD-GOLD (2007-20), Spain/SIDIAP (2010-20) and the Netherlands/IPCI (2008-20), standardised to a common data model. METHODS: Cohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)). RESULTS: We identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI.In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891-32,862)) to 2010 (17,793 (17,083-18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021-25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199-52,855)) to 2020 (14,571 (14,109-15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967-29,031)) to 2020 (4763 (4176-5409)). Subjects aged ≥65-79 years and men (in the UK and the Netherlands) initiated more frequently an ADD. CONCLUSIONS: Treatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.","keywords":"Humans Male Female *Dementia/drug therapy/epidemiology Aged Aged, 80 and over Middle Aged Netherlands/epidemiology Databases, Factual Time Factors Nootropic Agents/therapeutic use Spain/epidemiology United Kingdom/epidemiology Practice Patterns, Physicians'/trends Age Factors Drug Utilization/trends/statistics & numerical data cohort studies dementia drug utilization studies older people","issn":"0002-0729 (Print) 0002-0729","doi":"10.1093/ageing/afae106","year":"2024","bibtex":"@article{RN399,\r\n author = {Reyes, C. and Newby, D. and Raventós, B. and Verhamme, K. and Mosseveld, M. and Prieto-Alhambra, D. and Burn, E. and Duarte-Salles, T.},\r\n title = {Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study},\r\n journal = {Age Ageing},\r\n volume = {53},\r\n number = {5},\r\n note = {1468-2834 Reyes, Carlen Orcid: 0000-0001-8486-3265 Newby, Danielle Raventós, Berta Verhamme, Katia Mosseveld, Mees Prieto-Alhambra, Daniel Orcid: 0000-0002-3950-6346 Burn, Edward Duarte-Salles, Talita Real World Epidemiology/ Agency for Management of University and research/ Journal Article Multicenter Study Research Support, Non-U.S. Gov't England 2024/05/24 Age Ageing. 2024 May 1;53(5):afae106. doi: 10.1093/ageing/afae106.},\r\n abstract = {BACKGROUND: An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data. SETTING: Primary care data (country/database) from the UK/CPRD-GOLD (2007-20), Spain/SIDIAP (2010-20) and the Netherlands/IPCI (2008-20), standardised to a common data model. METHODS: Cohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)). RESULTS: We identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI.In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891-32,862)) to 2010 (17,793 (17,083-18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021-25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199-52,855)) to 2020 (14,571 (14,109-15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967-29,031)) to 2020 (4763 (4176-5409)). Subjects aged ≥65-79 years and men (in the UK and the Netherlands) initiated more frequently an ADD. CONCLUSIONS: Treatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.},\r\n keywords = {Humans\r\nMale\r\nFemale\r\n*Dementia/drug therapy/epidemiology\r\nAged\r\nAged, 80 and over\r\nMiddle Aged\r\nNetherlands/epidemiology\r\nDatabases, Factual\r\nTime Factors\r\nNootropic Agents/therapeutic use\r\nSpain/epidemiology\r\nUnited Kingdom/epidemiology\r\nPractice Patterns, Physicians'/trends\r\nAge Factors\r\nDrug Utilization/trends/statistics & numerical data\r\ncohort studies\r\ndementia\r\ndrug utilization studies\r\nolder people},\r\n ISSN = {0002-0729 (Print) 0002-0729},\r\n DOI = {10.1093/ageing/afae106},\r\n year = {2024},\r\n type = {Journal Article}\r\n}\r\n\r\n","author_short":["Reyes, C.","Newby, D.","Raventós, B.","Verhamme, K.","Mosseveld, M.","Prieto-Alhambra, D.","Burn, E.","Duarte-Salles, T."],"key":"RN399","id":"RN399","bibbaseid":"reyes-newby-ravents-verhamme-mosseveld-prietoalhambra-burn-duartesalles-trendsofuseandcharacterisationofantidementiadrugsusersalargemultinationalnetworkpopulationbasedstudy-2024","role":"author","urls":{},"keyword":["Humans Male Female *Dementia/drug therapy/epidemiology Aged Aged","80 and over Middle Aged Netherlands/epidemiology Databases","Factual Time Factors Nootropic Agents/therapeutic use Spain/epidemiology United Kingdom/epidemiology Practice Patterns","Physicians'/trends Age Factors Drug Utilization/trends/statistics & numerical data cohort studies dementia drug utilization studies older people"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/network/files/qwipow2DJsAxqNp83","dataSources":["TB9sD3avjy7bNxfgS","vDmJPYmHEKAT3tMNL","PcZMFHooKwpboi2he","jZMXEeHTfokmisJDv"],"keywords":["humans male female *dementia/drug therapy/epidemiology aged aged","80 and over middle aged netherlands/epidemiology databases","factual time factors nootropic agents/therapeutic use spain/epidemiology united kingdom/epidemiology practice patterns","physicians'/trends age factors drug utilization/trends/statistics & numerical data cohort studies dementia drug utilization studies older people"],"search_terms":["trends","use","characterisation","anti","dementia","drugs","users","large","multinational","network","population","based","study","reyes","newby","raventós","verhamme","mosseveld","prieto-alhambra","burn","duarte-salles"],"title":"Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study","year":2024}